🧫 Experiment Protocol
Clinicalproposed
SUMMARY
# Gap Junction Dysfunction Validation in Parkinson's Disease
## Background and Rationale
Gap junction dysfunction represents an emerging frontier in Parkinson's disease pathophysiology, offering a compelling mechanistic framework that bridges cellular communication deficits with the complex cascade of neurodegeneration characteristic of this debilitating movement disorder. This clinical investigation probes the fundamental hypothesis that compromised connexin and pannexin channel function serves
METHODOLOGY NOTES
**Phase 1: Patient Recruitment and Baseline Assessment (Weeks 1-8)**
• Recruit 120 Parkinson's disease patients (Hoehn & Yahr stages II-IV) and 60 age-matched healthy controls
• Obtain informed consent and perform comprehensive neurological evaluation using UPDRS-III
• Collect detailed medical history, medication records, and cognitive assessment (MoCA)
• Perform baseline brain MRI with dopamine transporter (DAT) imaging
• Collect cerebrospinal fluid (CSF) samples via lumbar puncture (n=60 PD, n=30 controls)
• Collect blood samples for plasma biomarker analysis
**Phase 2: Gap Junction Protein Analysis (Weeks 3-12)**
• Analyze CSF and plasma connexin-43 (Cx43) and pannexin-1 (Panx1) levels using ELISA
• Measure gap junction functionality markers: connexin phosphorylation status via Western blot
• Quantify pannexin-1 channel activity using ATP release assays in isolated PBMCs
• Assess connexin-43 protein expression and localization in available post-mortem brain tissue (n=20)
• Perfor